Japan’s Meiji Seika To Enlarge Generics Production Capacity In Thailand
This article was originally published in PharmAsia News
Japanese generic-drug maker Meiji Seika Kaisha plans to invest heavily in production in Thailand by the end of next year. The company, which currently markets 33 generics, 80 percent of which belong to other companies, plans to produce its own generics of some of the best-selling medicines. Plans call for investing $1.9 million to improve production lines of its Thai subsidiary, Thai Meiji Pharmaceutical, to increase capacity from the current 4 million tablets a year to 70 million. (Click here for more - a subscription may be required
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.